Evidence map›Paper›PMID 37036147›Full record

ArticleJournal of surgical oncology2023

Does non-metastatic gastric cancer of the cardia warrant a different treatment strategy?

Pranay S Ajay, Rachel NeMoyer, Subir Goyal, Jeffery M Switchenko, Yong Lin, Salma K Jabbour, Darren R Carpizo, Chrystal M Paulos, Timothy J Kennedy, Mihir M Shah

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Pranay S AjayDivision of Surgical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-9292-8345
Rachel NeMoyerDivision of Thoracic and Cardiothoracic Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Subir GoyalDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Jeffery M SwitchenkoDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Yong LinDepartment of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers University, New Brunswick, New Jersey, USA.
Salma K JabbourDivision of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey, USA.
Darren R CarpizoDivision of Surgical Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, New York, USA.
Chrystal M PaulosDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Timothy J KennedyDivision of Surgical Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey, USA.
Mihir M ShahDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-4665-5534
Emory University · USRutgers, The State University of New Jersey · USCleveland Clinic · USUniversity of Rochester · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

backgroundMultimodal treatment strategies with surgery as its centerpiece have been accepted as the standard of care in nonmetastatic cardia gastric cancer (CGC). There remains a lack of consensus regarding the optimal multimodal treatment strategy.

methodWe queried National Cancer Database from 2004 to 2016 to identify patients with resected nonmetastatic CGC who received perioperative chemotherapy (PEC), postoperative chemoradiation therapy (POCR), or postoperative chemotherapy (POC). A subgroup analysis was performed in optimally treated patients defined as initial chemotherapy within 45 days of diagnosis, resection within 45 days of diagnosis, negative margins, adjuvant chemotherapy within 90 days of resection, and standard radiation dose (45 Gy). Kaplan-Meier, Univariate analysis (UVA), and Multivariable analysis (MVA) were performed.

resultsWe identified 2387 patients. Median survival was 38.8 months in the PEC group, 36 months in the POCR group, and 32.3 months in the POC group (p = 0.1025). On UVA, patients treated with PEC had an association with improved survival (HR, 0.83; p = 0.037) when compared with POC. On MVA, no significant difference was noted in overall survival (OS) between PEC, POCR, and POC, similar to subgroup analysis of optimally treated cohort.

conclusionOS rate in nonmetastatic CGC is not significantly different between patients receiving PEC, POCR, or POC.

Indexed as

Stomach NeoplasmsCardiaChemoradiotherapyChemotherapy, AdjuvantCombined Modality TherapyHumansRetrospective Studiesmultimodal treatment in cardia gastric cancermultimodal treatment in gastric cancernonmetastatic cardia gastric cancernonmetastatic gastric cancerresectable cardia gastric cancer

Identifiers

PMID37036147
PMCPMC10915909
OpenAlexW4363646348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.